SciELO - Scientific Electronic Library Online

 
vol.32 issue2Imatinib in chronic myeloid leukemia: outcomes in routine clinical practiceCarboplatin Area Under the Curve dosing in pediatric patients: influence of glomerular filtration rate measurement author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de la OFIL

On-line version ISSN 1699-714XPrint version ISSN 1131-9429

Abstract

RODRIGUEZ-MARRODAN, B et al. Etanercept in rheumatic diseases: observational study. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.2, pp.173-177.  Epub Feb 13, 2023. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2022000200009.

Objetive:

1.- To know the response to biosimilar etanercept (E-BS) in naive patients and in patients who change from the reference (E-R), diagnosed with rheumatic diseases. 2.- To evaluate the economic impact of these actions.

Methods:

Retrospective observational study of 110 patients in treatment with etanercept (reference and/or biosimilar). Two groups of patients were analyzed: 62 patients who started with E-BS and 48 patients who change from E-R (switch), and they were compared with control groups. Variables analyzed: age, sex, diagnosis, treatment, units dispensed, treatment modifications, reason for suspension or change, date of suspension and follow-up time. The cost of using the biosimilar was compared with that of the reference one.

Results:

The retention rates observed were: 65% in the naive (p=0.002) and 90% in switch. In naive patients, the main reason for change was partial or insufficient response (90%) and a possible nocebo effect in switch (60%). No adverse reactions were observed. When comparing these groups with control populations, the main difference was the proportion of patients in whom treatment with E-BS was maintained versus ER, in naive patients (65% vs 34%; p=0.003) and in switch (90% vs 27%; p<0.0001). The use of E-BS meant a saving of € 653,668.

Conclusions:

The use of E-BS was not different from the E-R in terms of clinical results and, from the economic point of view, represents a substantial saving that should be considered as a measure that helps the sustainability of the system.

Keywords : Etanercept; biosimilar; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; cost analysis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )